Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Polycystic Ovary Syndrome 2Obesity 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Triple Negative Breast Neoplasms 1Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Peripheral Nervous System Diseases 1Pancreatic Neoplasms 1Overweight 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Motor Activity 1Mesothelioma 1Meningioma 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Localized Prostate Cancer 1Leukemia 1Leiomyosarcoma 1

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × TP53 Y220C Mutation × Tablets × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡